Industry Research Reports

Home > Reports > Pharma & Healthcare > Global and United States Beta-lactam and Beta-lactamase Inhibitors Market Report & Forecast 2022-2028

Global and United States Beta-lactam and Beta-lactamase Inhibitors Market Report & Forecast 2022-2028

Industry: Pharma & Healthcare

Published: 2022-04-23

Pages: 117 Pages

Report ld: 164676

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.

Market Analysis and Insights: Global and United States Beta-lactam and Beta-lactamase Inhibitors Market

This report focuses on global and United States Beta-lactam and Beta-lactamase Inhibitors market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Beta-lactam and Beta-lactamase Inhibitors market size is estimated to be worth US$ 27730 million in 2022 and is forecast to a readjusted size of US$ 31120 million by 2028 with a CAGR of 1.9% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Penicillins accounting for % of the Beta-lactam and Beta-lactamase Inhibitors global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Oral was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

Global key players of beta-lactam and beta-lactamase Inhibitors include Pfizer, USantibiotics, TEVA, Novartis (Sandoz), Antibiotice. Global top five manufacturers hold a share over 10%. Asia-Pacific is the largest market of beta-lactam and beta-lactamase Inhibitors, holds a share over 30%, followed by Europe, and North America, with a share of 30% and 20% respectively. In terms of product, cephalosporins is the largest segment, with a share over 38%. And in terms of application, the largest application is in Intravenous with a share about 50%.

Global Beta-lactam and Beta-lactamase Inhibitors Scope and Market Size
Beta-lactam and Beta-lactamase Inhibitors market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Beta-lactam and Beta-lactamase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Beta-lactam and Beta-lactamase Inhibitors market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
Penicillins
Cephalosporins
Carbapenems
Monobactams
Combinations

Segment by Application
Oral
Intravenous

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Pfizer
Novartis (Sandoz)
TEVA
Merck & Co.
AbbVie (Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
Wockhardt
Lupin Limited
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice

 1 Study Coverage
    1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction
    1.2 Global Beta-lactam and Beta-lactamase Inhibitors Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in US$ Million for the Year 2017-2028
        1.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume for the Year 2017-2028
    1.3 United States Beta-lactam and Beta-lactamase Inhibitors Outlook 2017 VS 2022 VS 2028
        1.3.1 United States Beta-lactam and Beta-lactamase Inhibitors Sales in US$ Million for the Year 2017-2028
        1.3.2 United States Beta-lactam and Beta-lactamase Inhibitors Sales in Volume for the Year 2017-2028
    1.4 Beta-lactam and Beta-lactamase Inhibitors Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States Beta-lactam and Beta-lactamase Inhibitors in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of Beta-lactam and Beta-lactamase Inhibitors Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 Beta-lactam and Beta-lactamase Inhibitors Market Dynamics
        1.5.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends
        1.5.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers
        1.5.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges
        1.5.4 Beta-lactam and Beta-lactamase Inhibitors Market Restraints
    1.6 Study Objectives
    1.7 Years Considered

 2 Market by Type
    2.1 Beta-lactam and Beta-lactamase Inhibitors Market Segment by Type
        2.1.1 Penicillins
        2.1.2 Cephalosporins
        2.1.3 Carbapenems
        2.1.4 Monobactams
        2.1.5 Combinations
    2.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
        2.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
        2.3.1 United States Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
    3.1 Beta-lactam and Beta-lactamase Inhibitors Market Segment by Application
        3.1.1 Oral
        3.1.2 Intravenous
    3.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application
        3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States Beta-lactam and Beta-lactamase Inhibitors Market Size by Application
        3.3.1 United States Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global Beta-lactam and Beta-lactamase Inhibitors Competitor Landscape by Company
    4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Company
        4.1.1 Top Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Ranked by Revenue (2021)
        4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturer (2017-2022)
        4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturer (2017-2022)
        4.1.4 Global Beta-lactam and Beta-lactamase Inhibitors Price by Manufacturer (2017-2022)
    4.2 Global Beta-lactam and Beta-lactamase Inhibitors Concentration Ratio (CR)
        4.2.1 Beta-lactam and Beta-lactamase Inhibitors Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2021
        4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base Distribution, Product Type
        4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Type
        4.3.3 Date of International Manufacturers Enter into Beta-lactam and Beta-lactamase Inhibitors Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States Beta-lactam and Beta-lactamase Inhibitors Market Size by Company
        4.5.1 Top Beta-lactam and Beta-lactamase Inhibitors Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Beta-lactam and Beta-lactamase Inhibitors Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States Beta-lactam and Beta-lactamase Inhibitors Sales by Players (2020, 2021 & 2022)

 5 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region
    5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size in Volume by Region (2017-2028)
        5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region: 2017-2022
        5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Forecast by Region (2023-2028)
    5.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Size in Value by Region (2017-2028)
        5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region: 2017-2022
        5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2017-2028
        6.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2017-2028
        6.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2017-2028
        6.4.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
        6.4.6 Colombia
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Corporation Information
        7.1.2 Pfizer Description and Business Overview
        7.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.1.5 Pfizer Recent Development
    7.2 Novartis (Sandoz)
        7.2.1 Novartis (Sandoz) Corporation Information
        7.2.2 Novartis (Sandoz) Description and Business Overview
        7.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.2.5 Novartis (Sandoz) Recent Development
    7.3 TEVA
        7.3.1 TEVA Corporation Information
        7.3.2 TEVA Description and Business Overview
        7.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.3.5 TEVA Recent Development
    7.4 Merck & Co.
        7.4.1 Merck & Co. Corporation Information
        7.4.2 Merck & Co. Description and Business Overview
        7.4.3 Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.4.5 Merck & Co. Recent Development
    7.5 AbbVie (Allergan)
        7.5.1 AbbVie (Allergan) Corporation Information
        7.5.2 AbbVie (Allergan) Description and Business Overview
        7.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.5.5 AbbVie (Allergan) Recent Development
    7.6 Sumitomo Dainippon
        7.6.1 Sumitomo Dainippon Corporation Information
        7.6.2 Sumitomo Dainippon Description and Business Overview
        7.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.6.5 Sumitomo Dainippon Recent Development
    7.7 Hikma
        7.7.1 Hikma Corporation Information
        7.7.2 Hikma Description and Business Overview
        7.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.7.5 Hikma Recent Development
    7.8 Aurobindo Pharma
        7.8.1 Aurobindo Pharma Corporation Information
        7.8.2 Aurobindo Pharma Description and Business Overview
        7.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.8.5 Aurobindo Pharma Recent Development
    7.9 Wockhardt
        7.9.1 Wockhardt Corporation Information
        7.9.2 Wockhardt Description and Business Overview
        7.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.9.5 Wockhardt Recent Development
    7.10 Lupin Limited
        7.10.1 Lupin Limited Corporation Information
        7.10.2 Lupin Limited Description and Business Overview
        7.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.10.5 Lupin Limited Recent Development
    7.11 Fresenius Kabi
        7.11.1 Fresenius Kabi Corporation Information
        7.11.2 Fresenius Kabi Description and Business Overview
        7.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered
        7.11.5 Fresenius Kabi Recent Development
    7.12 B. Braun
        7.12.1 B. Braun Corporation Information
        7.12.2 B. Braun Description and Business Overview
        7.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.12.4 B. Braun Products Offered
        7.12.5 B. Braun Recent Development
    7.13 USantibiotics
        7.13.1 USantibiotics Corporation Information
        7.13.2 USantibiotics Description and Business Overview
        7.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.13.4 USantibiotics Products Offered
        7.13.5 USantibiotics Recent Development
    7.14 Qilu Pharmaceutical
        7.14.1 Qilu Pharmaceutical Corporation Information
        7.14.2 Qilu Pharmaceutical Description and Business Overview
        7.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.14.4 Qilu Pharmaceutical Products Offered
        7.14.5 Qilu Pharmaceutical Recent Development
    7.15 ACS Dobfar
        7.15.1 ACS Dobfar Corporation Information
        7.15.2 ACS Dobfar Description and Business Overview
        7.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.15.4 ACS Dobfar Products Offered
        7.15.5 ACS Dobfar Recent Development
    7.16 Nichi-Iko (Sagent)
        7.16.1 Nichi-Iko (Sagent) Corporation Information
        7.16.2 Nichi-Iko (Sagent) Description and Business Overview
        7.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.16.4 Nichi-Iko (Sagent) Products Offered
        7.16.5 Nichi-Iko (Sagent) Recent Development
    7.17 Antibiotice
        7.17.1 Antibiotice Corporation Information
        7.17.2 Antibiotice Description and Business Overview
        7.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022)
        7.17.4 Antibiotice Products Offered
        7.17.5 Antibiotice Recent Development

 8 Industry Chain and Sales Channels Analysis
    8.1 Beta-lactam and Beta-lactamase Inhibitors Industry Chain Analysis
    8.2 Beta-lactam and Beta-lactamase Inhibitors Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 Beta-lactam and Beta-lactamase Inhibitors Distributors
    8.3 Beta-lactam and Beta-lactamase Inhibitors Production Mode & Process
    8.4 Beta-lactam and Beta-lactamase Inhibitors Sales and Marketing
        8.4.1 Beta-lactam and Beta-lactamase Inhibitors Sales Channels
        8.4.2 Beta-lactam and Beta-lactamase Inhibitors Distributors
    8.5 Beta-lactam and Beta-lactamase Inhibitors Customers

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Beta-lactam and Beta-lactamase Inhibitors CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Beta-lactam and Beta-lactamase Inhibitors Market Trends
    Table 3. Beta-lactam and Beta-lactamase Inhibitors Market Drivers
    Table 4. Beta-lactam and Beta-lactamase Inhibitors Market Challenges
    Table 5. Beta-lactam and Beta-lactamase Inhibitors Market Restraints
    Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Beta-lactam and Beta-lactamase Inhibitors Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Beta-lactam and Beta-lactamase Inhibitors Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Beta-lactam and Beta-lactamase Inhibitors Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturer, (M Units), 2017-2022
    Table 14. Global Beta-lactam and Beta-lactamase Inhibitors Sales Share by Manufacturer, 2017-2022
    Table 15. Global Beta-lactam and Beta-lactamase Inhibitors Price by Manufacturer (2017-2022) & (US$/Unit)
    Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Beta-lactam and Beta-lactamase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Beta-lactam and Beta-lactamase Inhibitors as of 2021)
    Table 18. Top Players of Beta-lactam and Beta-lactamase Inhibitors in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Type
    Table 20. Date of International Manufacturers Enter into Beta-lactam and Beta-lactamase Inhibitors Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Beta-lactam and Beta-lactamase Inhibitors Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Beta-lactam and Beta-lactamase Inhibitors Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Beta-lactam and Beta-lactamase Inhibitors Sales by Players, (M Units), 2020, 2021 & 2022
    Table 26. United States Beta-lactam and Beta-lactamase Inhibitors Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region (2017-2022) & (M Units)
    Table 29. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Forecast by Region (2023-2028) & (M Units)
    Table 30. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2017-2028) & (M Units)
    Table 33. North America Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region (2017-2028) & (M Units)
    Table 35. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2017-2028) & (M Units)
    Table 37. Europe Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2017-2028) & (M Units)
    Table 39. Latin Americaa Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2017-2028) & (M Units)
    Table 41. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Pfizer Corporation Information
    Table 43. Pfizer Description and Business Overview
    Table 44. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 45. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product
    Table 46. Pfizer Recent Development
    Table 47. Novartis (Sandoz) Corporation Information
    Table 48. Novartis (Sandoz) Description and Business Overview
    Table 49. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 50. Novartis (Sandoz) Product
    Table 51. Novartis (Sandoz) Recent Development
    Table 52. TEVA Corporation Information
    Table 53. TEVA Description and Business Overview
    Table 54. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 55. TEVA Product
    Table 56. TEVA Recent Development
    Table 57. Merck & Co. Corporation Information
    Table 58. Merck & Co. Description and Business Overview
    Table 59. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 60. Merck & Co. Product
    Table 61. Merck & Co. Recent Development
    Table 62. AbbVie (Allergan) Corporation Information
    Table 63. AbbVie (Allergan) Description and Business Overview
    Table 64. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 65. AbbVie (Allergan) Product
    Table 66. AbbVie (Allergan) Recent Development
    Table 67. Sumitomo Dainippon Corporation Information
    Table 68. Sumitomo Dainippon Description and Business Overview
    Table 69. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 70. Sumitomo Dainippon Product
    Table 71. Sumitomo Dainippon Recent Development
    Table 72. Hikma Corporation Information
    Table 73. Hikma Description and Business Overview
    Table 74. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 75. Hikma Product
    Table 76. Hikma Recent Development
    Table 77. Aurobindo Pharma Corporation Information
    Table 78. Aurobindo Pharma Description and Business Overview
    Table 79. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 80. Aurobindo Pharma Product
    Table 81. Aurobindo Pharma Recent Development
    Table 82. Wockhardt Corporation Information
    Table 83. Wockhardt Description and Business Overview
    Table 84. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 85. Wockhardt Product
    Table 86. Wockhardt Recent Development
    Table 87. Lupin Limited Corporation Information
    Table 88. Lupin Limited Description and Business Overview
    Table 89. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 90. Lupin Limited Product
    Table 91. Lupin Limited Recent Development
    Table 92. Fresenius Kabi Corporation Information
    Table 93. Fresenius Kabi Description and Business Overview
    Table 94. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 95. Fresenius Kabi Product
    Table 96. Fresenius Kabi Recent Development
    Table 97. B. Braun Corporation Information
    Table 98. B. Braun Description and Business Overview
    Table 99. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 100. B. Braun Product
    Table 101. B. Braun Recent Development
    Table 102. USantibiotics Corporation Information
    Table 103. USantibiotics Description and Business Overview
    Table 104. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 105. USantibiotics Product
    Table 106. USantibiotics Recent Development
    Table 107. Qilu Pharmaceutical Corporation Information
    Table 108. Qilu Pharmaceutical Description and Business Overview
    Table 109. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 110. Qilu Pharmaceutical Product
    Table 111. Qilu Pharmaceutical Recent Development
    Table 112. ACS Dobfar Corporation Information
    Table 113. ACS Dobfar Description and Business Overview
    Table 114. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 115. ACS Dobfar Product
    Table 116. ACS Dobfar Recent Development
    Table 117. Nichi-Iko (Sagent) Corporation Information
    Table 118. Nichi-Iko (Sagent) Description and Business Overview
    Table 119. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 120. Nichi-Iko (Sagent) Product
    Table 121. Nichi-Iko (Sagent) Recent Development
    Table 122. Antibiotice Corporation Information
    Table 123. Antibiotice Description and Business Overview
    Table 124. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 125. Antibiotice Product
    Table 126. Antibiotice Recent Development
    Table 127. Key Raw Materials Lists
    Table 128. Raw Materials Key Suppliers Lists
    Table 129. Beta-lactam and Beta-lactamase Inhibitors Customers List
    Table 130. Beta-lactam and Beta-lactamase Inhibitors Distributors List
    Table 131. Research Programs/Design for This Report
    Table 132. Key Data Information from Secondary Sources
    Table 133. Key Data Information from Primary Sources
List of Figures
    Figure 1. Beta-lactam and Beta-lactamase Inhibitors Product Picture
    Figure 2. Global Beta-lactam and Beta-lactamase Inhibitors Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Beta-lactam and Beta-lactamase Inhibitors Market Size 2017-2028 (US$ Million)
    Figure 4. Global Beta-lactam and Beta-lactamase Inhibitors Sales 2017-2028 (M Units)
    Figure 5. United States Beta-lactam and Beta-lactamase Inhibitors Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Beta-lactam and Beta-lactamase Inhibitors Market Size 2017-2028 (US$ Million)
    Figure 7. United States Beta-lactam and Beta-lactamase Inhibitors Sales 2017-2028 (M Units)
    Figure 8. United States Beta-lactam and Beta-lactamase Inhibitors Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Beta-lactam and Beta-lactamase Inhibitors Market Share in Global, in Volume (M Units) 2017-2028
    Figure 10. Beta-lactam and Beta-lactamase Inhibitors Report Years Considered
    Figure 11. Product Picture of Penicillins
    Figure 12. Product Picture of Cephalosporins
    Figure 13. Product Picture of Carbapenems
    Figure 14. Product Picture of Monobactams
    Figure 15. Product Picture of Combinations
    Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Type in 2022 & 2028
    Figure 17. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 18. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2017-2028)
    Figure 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) & (M Units)
    Figure 20. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2017-2028)
    Figure 21. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2028) & (US$/Unit)
    Figure 22. United States Beta-lactam and Beta-lactamase Inhibitors Market Share by Type in 2022 & 2028
    Figure 23. United States Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 24. United States Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2017-2028)
    Figure 25. United States Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) & (M Units)
    Figure 26. United States Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2017-2028)
    Figure 27. United States Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2028) & (US$/Unit)
    Figure 28. Product Picture of Oral
    Figure 29. Product Picture of Intravenous
    Figure 30. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application in 2022 & 2028
    Figure 31. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 32. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2017-2028)
    Figure 33. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) & (M Units)
    Figure 34. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2017-2028)
    Figure 35. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2028) & (US$/Unit)
    Figure 36. United States Beta-lactam and Beta-lactamase Inhibitors Market Share by Application in 2022 & 2028
    Figure 37. United States Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 38. United States Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2017-2028)
    Figure 39. United States Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) & (M Units)
    Figure 40. United States Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2017-2028)
    Figure 41. United States Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2028) & (US$/Unit)
    Figure 42. North America Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2017-2028 (M Units)
    Figure 43. North America Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 44. United States Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Canada Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Europe Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2017-2028 (M Units)
    Figure 47. Europe Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. Germany Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. France Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. U.K. Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Italy Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Russia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2017-2028 (M Units)
    Figure 54. Asia-Pacific Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 55. China Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Japan Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. South Korea Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. India Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Australia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. China Taiwan Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Indonesia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Thailand Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Malaysia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2017-2028 (M Units)
    Figure 65. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 66. Mexico Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Brazil Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Argentina Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Colombia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2017-2028 (M Units)
    Figure 71. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 72. Turkey Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Saudi Arabia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. UAE Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Beta-lactam and Beta-lactamase Inhibitors Value Chain
    Figure 76. Beta-lactam and Beta-lactamase Inhibitors Production Process
    Figure 77. Channels of Distribution
    Figure 78. Distributors Profiles
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.

Market Analysis and Insights: Global and United States Beta-lactam and Beta-lactamase Inhibitors Market

This report focuses on global and United States Beta-lactam and Beta-lactamase Inhibitors market, also covers the segmentation data of other regions in regional level and county level.

Segment by Type
Penicillins
Cephalosporins
Carbapenems
Monobactams
Combinations

Segment by Application
Oral
Intravenous

Industry: Pharma & Healthcare

Published: 2022-04-23

Pages: 117 Pages

Report ld: 164676

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 4350.00

Multi Users License

USD 6525.00

Corporate Users License

USD 8700.00

/uploads/payment/payIcon/masterCard-01.svg

/uploads/payment/payIcon/american-express-01.svg

/uploads/payment/payIcon/diners-club-01.svg

/uploads/payment/payIcon/discover-4-01.svg

Add to Cart

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

Speak To Our Analyst >>

WHAT QYRESEARCH OFFER?